FOXO4-DRI Side Effects: What Is Known, What Is Not, and What to Watch For

The medication this page covers:

The price is all-in: medication, physician review, refill management and shipping, with no membership fee. FOXO4-DRI at Pepti is compounded by a PCAB-accredited, FDA-registered US 503A pharmacy. Compounded medications are not FDA approved.

FOXO4-DRI was designed in the laboratory of Peter de Keizer at Erasmus University Medical Center and first described in a 2017 paper in Cell. Every study since has been in mice or in cells in a dish. There are no randomised human trials and no published non-randomised human trials.

The mouse work also used a different route: a short course of intermittent intraperitoneal injection, not weeks of subcutaneous dosing. So even the mouse tolerability data was not gathered the way the compounded product is used.

Two features make FOXO4-DRI unusual. It is a D-retro-inverso peptide, built from mirror-image D-amino acids assembled in reverse order, so proteases do not recognise it and it survives far longer in the body than a natural sequence would. And it carries a short cell-penetrating tail borrowed from the HIV TAT protein, which lets it cross cell membranes and reach p53 in the nucleus.

Because of that, its behaviour in the body is less predictable from first principles than a natural peptide's, and immune reactions to unusual peptide chemistry are a theoretical concern that has not been studied in people. Nothing in the live research reports such a reaction; it has simply never been looked for in humans.

With the injection

What gets reported clinically is mostly at the injection site: redness, mild soreness and occasional bruising. Rotating sites between the abdomen and thigh, so the same spot is not used repeatedly, is the usual answer. Technique is in how to inject peptides safely.

Things people expect that the research does not describe

Senescent cell clearance, if it happens, is not something you would feel. FOXO4-DRI is not a stimulant, not a sedative and not a direct anti-inflammatory, and there is no described acute effect. Most people should expect to notice nothing during a first vial. Not feeling anything is not a side effect, and it is not a reason to change your dose.

p53 and cancer

Senescence is one of the body's defences against cancer: a cell with dangerous damage is parked rather than allowed to divide. FOXO4-DRI's described action is to disrupt the FOXO4 and p53 interaction so that parked cells die. Removing them is in principle the safer outcome, but the compound acts on p53, the central tumour-suppressor protein, and nobody has studied what that means over time in humans. A personal or family history of cancer is a reason to discuss it carefully with your physician before starting. See can peptides cause cancer.

Senolytics and pulmonary hypertension

A 2023 study in Circulation reported that eliminating senescent cells in the pulmonary vessels of mice, using senolytic interventions, worsened pulmonary hypertension rather than improving it. That is a finding about senolytics as a class, in one tissue, in mice, and it has not been shown in people. It is the clearest published example of a senolytic doing something unexpected. Anyone with pulmonary hypertension or significant lung disease should raise it at intake.

Because there is no interaction list, the intake asks for every medication and supplement you take, and a physician reviews it rather than a form.

Message your care team, through your account, if:

• Injection-site redness, swelling or soreness spreads, gets worse, or does not settle within a few days.
• You notice a rash, hives or a reaction away from the injection site.
• Any new symptom persists, including breathlessness or chest discomfort.
• You are diagnosed with cancer or a lung condition, or start treatment for one.
• You become pregnant or are planning a pregnancy.
• You start any new medication or supplement.
• Your label and your syringe seem not to match. Do not inject; ask first.

Do not change your own dose in response to a side effect, and do not take two doses to make up for a missed one. Your physician sets your directions after reviewing your intake, and any new directions are printed on the next label.

Call 911 or go to the nearest emergency department for:

• Swelling of the face, lips, tongue or throat.
• Trouble breathing or swallowing.
• Chest pain or sudden severe breathlessness.
• A widespread rash or hives with feeling faint.
• Any reaction that is severe or spreading quickly.

If you think you injected far more than your directions, call Poison Control at 1-800-222-1222 and message your care team. Get emergency care first, then tell your physician.

Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.

As of September 2026 the FDA has not evaluated FOXO4-DRI at all. It does not appear in Category 1, Category 2 or Category 3 of the FDA's 503A nominated-substances document, most recently updated 14 May 2026, and it is absent from the FDA's page of bulk substances that may present significant safety risks, current as of 22 April 2026. It was not on the agenda of the Pharmacy Compounding Advisory Committee's July 2026 meeting or the meeting announced for early 2027. It is not FDA approved, and compounded medications never are.

FOXO4-DRI has a well-defined mechanism and a thin safety record. The mouse studies consistently report it was tolerated, which is the extent of what is known. No human has been treated in a published study, so the questions that matter most for a person, how it behaves in the body, what happens with repeated courses, and what acting on p53 means over years, are open. The sensible reading is to treat it as an experimental compound: report anything new, raise cancer and lung history before starting, and do not read the absence of human reports as evidence of safety. The general guide is peptide side effects: what to watch for, and the dose arithmetic is in FOXO4-DRI dosage.

FOXO4-DRI cannot be bought legitimately without a prescription. Products sold "for research use only" have no accountable pharmacy behind their identity, purity, sterility or concentration. The prescription route:

1. Complete a free online intake covering your history, including any cancer or lung history, your medications, and what you want help with.
2. A physician licensed in your state reviews it, usually within 24 hours.
3. If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription. Lot test results are published at /quality/lab-results.
4. It ships refrigerated with ice packs, with sterile syringes and alcohol prep pads, and your directions printed on the vial.
5. Your care team stays reachable for side effects and questions. Refills run every 28 days, one vial per fill.

Pepti is cash-pay and does not bill insurance. Step by step: how to get FOXO4-DRI prescribed online.